LONN 📈 Lonza - Overview

Lonza Group AG is a multinational corporation that provides an extensive range of products and services to the pharmaceutical, biotech, and nutrition industries globally. With operations spanning across Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and other international markets, the company has established itself as a key player in the life sciences sector. Its business is divided into four primary segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients, each catering to distinct aspects of the pharmaceutical and biotech value chain.

The Biologics segment is focused on the contract development and manufacturing of biopharmaceuticals, supporting clients throughout the entire product lifecycle. This encompasses both drug substance and drug product manufacturing for clinical and commercial purposes. By offering a comprehensive suite of services, Lonza enables its clients to bring their biopharmaceutical products to market efficiently. In contrast, the Small Molecules segment operates as an integrated development and manufacturing service provider, specializing in small molecule drug substances and their intermediates. This segment's capabilities extend to particle engineering and drug product packaging, providing customers with a one-stop solution for their small molecule needs.

The Cell & Gene segment is at the forefront of developing technologies and platforms aimed at industrializing the manufacturing processes and production of cell and gene therapies. This includes contract development and manufacturing services, as well as regulatory support for a variety of therapies, such as allogeneic and autologous cell therapies, exosome-based therapies, and viral vector gene therapies. A notable offering within this segment is the Cocoon platform, a closed automated system designed for patient-scale cell therapy manufacturing. Additionally, the company provides specialty raw materials and enabling technology solutions for cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets, further solidifying its position in this rapidly evolving field.

The Capsules & Health Ingredients segment rounds out Lonza's portfolio by offering capsules, dosage form solutions, and health ingredients tailored to the needs of pharmaceutical and nutraceutical customers. This diversity in product and service offerings allows Lonza to address a broad spectrum of client requirements, from the development and manufacturing of pharmaceuticals and biopharmaceuticals to the provision of health-promoting ingredients. Founded in 1897 and headquartered in Basel, Switzerland, Lonza Group AG has a long history of innovation and customer-centricity, with its operations and offerings continually evolving to meet the changing needs of the life sciences industry.

With a strong online presence, including its website at https://www.lonza.com, and listed with the ISIN CH0013841017 as a common stock, Lonza falls under the Biotechnology sub-industry within the GICS classification system. This classification reflects the company's significant involvement in the development and application of biotechnology across its various business segments. As a publicly traded company, Lonza is committed to transparency and accountability, ensuring that its operations are not only innovative and customer-focused but also adhere to the highest standards of corporate governance and sustainability.